Sunesis Pharmaceuticals SNSS will be releasing its next round of earnings this Tuesday, August 11. For all of the relevant information, here is your guide for Tuesday's Q2 earnings announcement.
Earnings and Revenue
Sunesis Pharmaceuticals EPS is expected to be around $-0.06, according to sell-side analysts. Sales will likely be near $190.00 thousand. In the same quarter last year, Sunesis Pharmaceuticals posted EPS of $-0.09. The analyst consensus estimate would represent a 33.33% increase in the company's earnings. Here's how the company's reported EPS has stacked up against analyst estimates in the past:
| Quarter | Q1 2020 | Q4 2020 | Q3 2019 | Q2 2019 |
|---|---|---|---|---|
| EPS Estimate | -0.07 | -0.07 | -0.08 | -0.10 |
| EPS Actual | -0.05 | -0.05 | -0.06 | -0.09 |
| Revenue Estimate | 190.00 K | 310.00 K | 200.00 K | 150.00 K |
| Revenue Actual | 120.00 K | 2.07 M | 0 | 0 |
Stock Performance
Over the last 52-week period, shares are down 57.29%. Given that these returns are generally negative, long-term shareholders are probably upset going into this earnings release.
Don't be surprised to see the stock move on comments made during its conference call. Sunesis Pharmaceuticals is scheduled to hold the call at 16:30:00 ET and can be accessed here: https://edge.media-server.com/mmc/p/6hztwkz9
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
